Table 3.

Participants Who Did Not Receive Lorazepam (N=23): Least Squares Means Estimates of Brief Psychiatric Rating Scale (BPRS) Factor Scores and Scale for the Assessment of Negative Symptoms (SANS) scores over time

		Placebo		Omega 3		Treatment-by-time interaction				Effect of Treatment
		Mean	SE	Mean	SE	F	Df	df	p	F	df	df	p
BPRS Factor Scores1
Negative symptoms						0.71	10	117	0.7133	0.30	1	117	0.5872
	baseline	4.5000	0.5733	5.3636	0.6414
	week 16	5.9250	0.9014	4.8257	0.8326
Depression-anxiety						2.27	10	117	0.0184	0.84	1	117	0.3605
	baseline	6.1667	0.8510	8.3636	0.6849
	week 16	6.1801	1.4345	3.4542	0.8983
Hostile-uncooperativeness2						1.41	10	117	0.1844	2.67	1	117	0.1051
	baseline	6.5833	0.4304	5.9091	0.3299
	week 16	5.8269	0.7040	4.7586	0.4120
Positive symptoms3						0.45	10	117	0.9181	0.72	1	117	0.3977
	baseline	12.2500	0.8454	12.3636	0.7569
	week 16	7.2597	1.2787	5.8353	0.9049
SANS Global Scores
Affective flattening						0.76	10	114	0.6690	0.70	1	114	0.4050
	baseline	1.5000	0.2199	1.8182	0.2427
	week 16	1.9015	0.3202	1.9148	0.3172
Alogia						1.15	10	114	0.3326	0.82	1	114	0.3668
	baseline	1.2500	0.1818	1.5455	0.1374
	week 16	1.5748	0.2723	1.0313	0.1745
Avolition/apathy4						1.61	10	114	0.1129	2.20	1	114	0.1405
	baseline	1.7500	0.2729	2.0000	0.2521
	week 16	2.8167	0.4126	1.8015	0.3332
Asociality/anhedonia5						1.57	10	113	0.1260	2.84	1	113	0.0945
	baseline	1.6667	0.2393	1.6364	0.2469
	week 16	2.3600	0.3524	1.4822	0.3227

¹defined in (Ventura et al., 2000)

²effect of time, F=2.93, df=10,117; p=0.0026

³effect of time, F=13.89, df=10,117; p<0.0001

⁴effect of time, F=2.83, df=10,144; p<=0.0035

⁵effect of time, F=2.20, df=10,113; p=0.0226